Drug Profile
AK 115
Alternative Names: AK-115Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Monoclonal antibodies; Non-opioid analgesics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer pain; Pain
Most Recent Events
- 26 Dec 2023 Akeso Biopharma completes a phase Ia trial in Cancer pain in China (Parenteral) (prior to December 2023) (Akeso Biopharma pipeline, December 2023)
- 26 Dec 2023 Akeso Biopharma completes a phase Ia trial in Pain in China (Parenteral) (prior to December 2023) (Akeso Biopharma pipeline, December 2023)
- 13 Jan 2023 Preclinical development in Cancer-pain is ongoing in China (Parenteral, Injection) (Akeso Biopharma pipeline, January 2023)